Chloé Grasselly

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

E. Matera, C. Dumontet, L. Jordheim, 2018, Front. Immunol..

Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy

E. Matera, C. Dumontet, Morgane Denis, 2023, Frontiers in Immunology.

IN VIVO SYNGENEIC TUMOR MODELS WITH ACQUIRED RESISTANCE TO ANTI-PD-1/PD-L1 THERAPIES.

C. Klein, E. Matera, C. Dumontet, 2022, Cancer immunology research.